LEADER 06473nam 2201777z- 450 001 9910404086803321 005 20210211 010 $a3-03928-747-8 035 $a(CKB)4100000011302270 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54359 035 $a(oapen)doab54359 035 $a(EXLCZ)994100000011302270 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNatural Products and Drug Discovery 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (392 p.) 311 08$a3-03928-746-X 330 $aNatural products hold a prominent position in the current discovery and development of drugs and have diverse indications for both human and animal health. Plants, in particular, play a leading role as a source of specialized metabolites with medical effects. Other organisms, such as marine and terrestrial animals and microorganisms, produce very important drug candidate molecules. Specialized metabolites from these varied natural sources can be used directly as bioactive compounds or drug precursors. In addition, due to their broad chemical diversity, they can act as drug prototypes and/or be used as pharmacological tools for different targets. Some examples of natural metabolites that have been developed into useful medical drug are cardiotonic digoxin from Digitalis sp., antimalarial artemisinin from Artemisia annua, anti-cancer taxol from Taxus sp., or podophyllotoxin from Podophyllum peltatum, which served as a synthetic model for the anti-cancer etoposide. The study of natural products is still attracting great scientific attention and their current importance, as a valuable lead for drug discovery, is undebatable. I cordially invite authors to contribute original articles, as well as survey articles, that give the readers of Molecules **MOLECULES NEEDS TO BE ITALICIZED** updated and new perspectives on natural products in drug discovery, including but not limited to natural sources, identification and separation of bioactive phytochemicals, standardization, new biological targets, pre-clinical and clinical trials, pharmacological effects/side effects, and bioassays. 606 $aBiology, life sciences$2bicssc 610 $a2? 610 $a4?-dihydroxy-6?-methoxy-3? 610 $a5?-dimethylchalcone (DMC) 610 $aACE inhibitory peptide 610 $aacetylated astragalosides 610 $aaging 610 $aangiogenesis 610 $aanti-inflammatory activity 610 $aantihypertensive 610 $aantimicrobial agents 610 $aantimicrobial resistance 610 $aantinociceptive 610 $aantioxidant activity 610 $aartemisinin 610 $aAstragalus boeticus L. 610 $aBacopa monnieri 610 $abioactive peptides 610 $abioactivities of natural products 610 $abiotechnology 610 $aC-glycoside 610 $aCa2+ 610 $acancer 610 $acardamonin 610 $acardiovascular disease 610 $acelastrol 610 $acerebellum 610 $achemical derivatization 610 $achemosystematics 610 $achromatography 610 $acircular dichroism 610 $aCleistocalyx operculatus 610 $aCuba 610 $acytokines 610 $acytotoxic activity 610 $acytotoxicity-guided 610 $aDasycladus vermicularis 610 $adementia 610 $adevil's claw 610 $adiabetes 610 $adiabetic neuropathy 610 $adihydrochalcones 610 $aDryopteris fragrans 610 $aEruca sativa 610 $aESI-MS/MS 610 $aFabaceae 610 $aFideloside 610 $aflavonoid 610 $aflavonoids 610 $aFSE 610 $aglucoerucin 610 $aglucosinolates 610 $aGLUT4 610 $aglutamate 610 $agrowth inhibitory activity 610 $aH2S 610 $aHarpagophytum procumbens 610 $aharpagoside 610 $aHPLC 610 $aHPLC-ESI-microTOF-Q-MS/MS 610 $ahuman colon cancer cell lines 610 $aHumulus lupulus 610 $ahypertension 610 $aimmuno-regulation activity 610 $aImperata cylindrica 610 $ainflammation 610 $aisoflavones 610 $aisolation and quantification 610 $aketamine 610 $aKv7 potassium channels 610 $aL6 cell 610 $aLamiales 610 $aLC-MS 610 $aLeea indica 610 $aLeishmania mexicana mexicana 610 $amalaria 610 $amarine peptides 610 $amarine resources 610 $amass spectrometry 610 $ametabolomics 610 $amethicillin-resistant Staphylococcus aureus 610 $amigration 610 $amolecular network 610 $amultivariate data analysis 610 $an/a 610 $aNADPH oxidases 610 $anatural products 610 $aneuropathic pain 610 $aNMR 610 $aopioid 610 $aOrobanchaceae 610 $aOrobanche s.l. 610 $aoxidative stress 610 $aPANC-1 610 $aphenolic derivatives 610 $aphenolics 610 $aphenylethanoid glycosides 610 $aphenylpropanoid glycosides 610 $aPhyllanthus chamacristoides 610 $aPhyllanthus orbicularis 610 $aPhyscomitrella patens 610 $apPancreatic cancer 610 $aprenylated phenolic compounds 610 $aproanthocyanidins 610 $aproliferation 610 $apsychosis 610 $asecondary metabolites 610 $asesquiterpenoids 610 $asiphonous green algae 610 $aspagyric tincture 610 $aspectroscopic analysis 610 $astereochemistry 610 $asulfated coumarins 610 $asynergy 610 $aT2DM 610 $aterpenes 610 $aterpenoids 610 $atraditional medicine 610 $aTrifolium 610 $aTRPV1 610 $aTrypanosoma brucei brucei 610 $azebrafish 615 7$aBiology, life sciences 700 $aAvato$b Pinarosa$4auth$01297601 906 $aBOOK 912 $a9910404086803321 996 $aNatural Products and Drug Discovery$93024600 997 $aUNINA